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A B S T R A C T  
Objective: To study the prevalence of hepatitis B virus infection amongst pregnant women. 
Subjects and Methods: A hospital based cross-sectional study was conducted among pregnant women who attended 
antenatal care clinic for routine pregnancy check-up from July 2016 to February 2017. Sample size was calculated by 
using WHO sample size calculator and 900 pregnant women were enrolled in the study. Data were collected by face to 
face interview using a questionnaire. Serum was withdrawn from each study subject and tested for Hepatitis B Surface 
Antigen (HBsAg) by an enzyme linked immunosorbent assay (ELISA) test kit. Data were analyzed using SPSS version 
20. 
Results: The prevalence of HBV infection among pregnant women attending Benazir Bhutto Hospital, Rawalpindi, was 
found to be 2.78%. 
Conclusion: This study determined that the prevalence of HBV infection among pregnant women in Rawalpindi was 
2.78%, implying that it is intermediate endemic area. 
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I n t r o d u c t i o n  
 
Hepatitis B infection is caused by hepatitis B virus. It is an 
enveloped DNA virus that infects liver and causes 
hepatocellular necrosis and inflammation. HBV infection is 
one of the serious public health problem worldwide.1 
Many of the carriers do not realize that they are infected 
with virus rendering the HBV to be known as a “silent 
killer”. Worldwide, it is estimated that 350 million people 
are chronically infected with hepatitis B.2 Recent reports 
demonstrated that 68,600 people die of HBV infection and 
globally every year, more than 300,000 deaths are due to 
liver cancer secondary to hepatitis B.3 In Pakistan, the 
situation is worse than in the developed countries of the 
world. HBV infection is a contagious disease that can be 
transmitted vertically from mothers to their neonates or 
horizontally through blood products and body secretions.4 
Chronic hepatitis B infection in the female population has 
implications not just for the individual but for her children 
as well.5 HBV positive mothers with an HBsAg positive 
status can vertically transmit the infection to their infants.6 
This risk of transmission may increase, if the mother 
develops the HBV infection during the third trimester of 
pregnancy.7 The prevalence of HBV infection among 
women of childbearing age may be as high as 2–8 % in 
China8 whereas in the USA it is only 0.4 %.9 
Acute HBV infection during pregnancy is less severe and 
is not directly associated with increased mortality or 
teratogenicity.10 However, increased incidences of low 
birth weight and prematurity in infants born to mothers 
with acute HBV infection have been recorded. 
Furthermore, acute HBV infection in early pregnancy has 
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been associated with a 10% perinatal transmission rate.10 
Transmission rates as high as 60% have been reported to 
increase significantly if acute infection occurs at or near 
the time of delivery.11 Although there is a safe and 
effective vaccine, 50 million new cases are diagnosed 
annually worldwide.12 Majority of new diagnoses, 
however, are classified as mother-to-child transmission, 
especially in regions with high prevalence of the 
disease.13 The risk for development of chronic HBV 
infection is inversely related to the age of exposure. 
Infants exposed to HBV progress to a chronic infection in 
90% of cases, whereas toddlers and young children clear 
the virus in only 50% of cases.14 Infection in the adult 
population, however, is associated with only a 5% rate of 
progression to chronic disease. In adults, exposure to 
hepatitis B typically presents with an acute syndrome and 
viral clearance is more prevalent.15 
Viral hepatitis during pregnancy is associated with a high 
risk of maternal complications.16 Administration of 
hepatitis B immunoglobulin and hepatitis B vaccine to 
infants at birth, followed by completion of the vaccine 
series, prevented approximately 95% of HBV 
transmission from HBsAg-positive mothers to their 
infants.16  
HBV carrier status is relatively common among pregnant 
women, especially in endemic countries such as Pakistan. 
However, data on the epidemiology of HBV infection in 
Pakistan are limited. The magnitude of the problem is not 
yet addressed in many parts of Pakistan. The present 
study was planned to determine the prevalence of HBV 
infection among pregnant women in Rawalpindi district of 
Pakistan. 
S u b j e c t s  a n d  M e t h o d s  
This cross sectional study was conducted at Benazir 
Bhutto Hospital, Rawalpindi, Pakistan from July 2016 to 
February 2017. It is a tertiary care hospital that shares a 
major load of Gynecology & Obstetrics patients and 
provides antenatal and other specialized obstetric 
services for the inhabitants of the Rawalpindi district and 
beyond. The study population was all consecutive 
pregnant females, who attended antenatal care clinic for 
check-up services at Benazir Bhutto Hospital, Rawalpindi. 
Sample size was calculated by using WHO sample size 
calculator, total of 900 pregnant women were included in 
the study. All study participants were informed about the 
study and assured about the confidentiality of data. A 
written informed consent was obtained from all 
participants.  
Approximately 5 ml of venous blood was collected from 
each individual in a gel vacutainer by an experienced 
laboratory technologist. The samples were centrifuged at 
2000 revolutions per minutes (rpm) for 5 minutes in order 
to obtain a clear supernatant serum. The sera were then 
stored at -20°C prior to the serologic assay of HBV. 
Screening for HBsAg was performed using HBsAg ELISA 
kit. It is a solid-phase sandwich- immunoassay, which 
employs specific monoclonal antibodies and polyclonal 
antibodies. Protocol for the measurement was done 
according to the manufacturer's instruction and reading 
was done at O.D. of 450 nm with an EIA plate reader. The 
tests ran were validated and results were interpreted 
according to the manufacturer's instruction. Positive and 
negative controls were run along with each batch of 
ELISA test kit. Data were entered into SPSS version 20 
for analysis.  
R e s u l t s  
A total of 900 blood samples were collected from 
pregnant women and then screened for HBV infection 
using the ELISA kit. Among total of 900 pregnant females, 
2.78% (n=25) were positive and 97.2% (n=875) were 
negative for HBs Antigen.  
D i s c u s s i o n  
Hepatitis is considered to be an important public health 
problem for which reliable screening tests do exist. The 
hepatitis B virus infection is a common cause of morbidity 
and mortality globally.17 It is estimated that about 2 billion 
people worldwide have serologic evidence of hepatitis B, 
of which 350 million are chronic carrier.17 About 1.2 million 
die annually from chronic hepatitis, cirrhosis, and 
hepatocellular carcinoma.18 Of the estimated 350 million 
chronically infected individuals, about 50% acquired their 
infections either perinatally or in early childhood.9 Most 
pregnant women with HBV infection are chronic carriers.19 
Chronic hepatitis B virus infection due to mother-to-child 
transmission during perinatal period remains an important 
public health problem.20 High rate of mother-to-child 
transmission of HBV in an endemic country is of 
concern.21 Hepatitis B virus infection characterized by 
HBsAg positivity during pregnancy is a well-recognized 
issue in developing countries.22 
The prevalence of chronic HBV infection worldwide is 
categorized as high (≥8%), intermediate (2–7%), and low 
(<2%) endimicity.23 The prevalence of HBV infection 
varies markedly throughout regions of the world, being 
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highly endemic in developing regions with large 
population such as South East Asia, China and sub-
Saharan Africa, where at least 8% of the population are 
HBV chronic carrier.23 Transmission of HBV from carrier 
mothers to their babies appears to be the most important 
factor in determining the prevalence of the infection in 
high endemic areas.24 There are three possible routes of 
transmission of HBV from infected mothers to infants: 
transplacental transmission of HBV in utero; natal 
transmission during delivery; or postnatal transmission 
during care or through breast milk.24 In developed 
countries, the incidence of hepatitis is around 0.1% 
whereas in developing countries it ranges from 3 to 20% 
and even higher in some areas.25 In Africa and Asia, the 
prevalence of HBV is > 8% and 2 billion people have 
markers of current or past infection with HBV.26 About half 
of new infections result from vertical transmission during 
pregnancy, a statistic that is linked to the fact that HBV 
screening is not part of routine antenatal care in the 
area.25 
In this study, we found that the prevalence of HBsAg 
among study participants was 2.78%. Overall prevalence 
of HBV infection among pregnant women in Rawalpindi is 
intermediate (2.78%) endemic area according to the WHO 
classification criteria. The frequency of HBsAg among 
pregnant women in our study was comparable with 
studies conducted in other parts of world. In a study 
conducted in KPK (Khaber Pukhtunkhawa), prevalence of 
HBV in pregnant women was reported to be 1.16%.27 In a 
study by Abdi Umare et al, the frequency of HBsAg 
among study participants was 6.9%.28 The HBsAg 
prevalence rate of 3.8% was found among enrolled 
pregnant participants in Kenya indicating intermediate 
endemicity.29 The seroprevalence of HBsAg was 8.3% 
among pregnant women in Nigeria.30 Prevalence of 
HBsAg among pregnant women in China was noted to be 
2.5% as reported by Ai-Ming Cui et al.19 
The American Congress of Obstetrics and Gynecology 
recommend that every pregnant patient should undergo 
screening for HBV.31 All infants require the HBV 
vaccination series and Hepatitis B immunoglobulin within 
12 hours of birth. 31 
C o n c l u s i o n  
This study shows that Hepatitis B virus infection is of 
intermediate endemicity in Rawalpindi, with prevalence 
rate 2.78%. Early screening and detection of infected 
pregnant females, immunoprophylaxis and surveillance 
for exposed newborns are essential components of health 
care system. 
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